London 2012: prescribing for athletes in ophthalmology

• Published in: Eye (London) Vol. 26; no. 8; pp. 1036 - 1038
• Main Authors: Nicholson, R G H, Thomas, G P L, Potter, M J, Norris, J H
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.08.2012; Nature Publishing Group
• Subjects: 692/699; 692/700/565/1436; 706/648/180; Athletes; Biological and medical sciences; Clinical Study; Doping in Sports - prevention & control; Humans; Inappropriate Prescribing - prevention & control; Laboratory Medicine; London; Medical sciences; Medicine; Medicine & Public Health; Miscellaneous; Ophthalmic Solutions - administration & dosage; Ophthalmology; Ophthalmology - standards; Pharmaceutical Preparations - administration & dosage; Pharmaceutical Sciences/Technology; Pharmacopoeias as Topic; Physician's Role; Practice Guidelines as Topic; Surgery; Surgical Oncology; World; United Kingdom; Europe; London; ophthalmology; medication; athlete; World Anti-Doping Association; doping in sports; Drug; Prescription; Chemotherapy; Sport; Treatment; Association; Ophthalmology; Athlete
• ISSN: 0950-222X; 1476-5454
• DOI: 10.1038/eye.2012.139

Aims Prescribing for athletes requires an up-to-date knowledge of the World Anti-Doping Agency’s list of prohibited substances. As the London 2012 Olympic Games attract athletes from around the world, we review the current guidelines with respect to all medications licensed for ophthalmic use in the United Kingdom. We describe the process that an ophthalmologist can use to check for permissible medications and also highlight treatments that are contraindicated. Methods We systematically reviewed all 77 drugs listed in Section 11 of the British National Formulary (Issue 63) for use in the treatment of ophthalmic conditions, and referenced these against the 2012 Prohibited List published by the World Anti-Doping Agency. Results The majority of ophthalmic preparations are suitable for use in- and out-of-competition. Some preparations, such as glucocorticoids, are prohibited when administered systemically but permitted for topical administration. Beta-blockers are prohibited in-competition and oral carbonic anhydrase inhibitors are prohibited in- and out-of competition. Conclusion The 2012 Prohibited List has important implications for the pharmacological treatment of ophthalmic conditions in athletes. Clinicians prescribing for athletes have a duty to familiarise themselves with the list in order to avoid causing significant damage to their patient’s career and reputation.